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. Structure of cordycepin and adenosine. Figure S2 . Cordycepin has no significant effect on inducing HUVEC apoptosis. (A) HUVECs were treated with 0-25 μg/mL cordycepin for 24 h. The percentage of sub-G1 cells was examined by flow cytometry analysis. Scale bars: mean ± SD. (B) HUVECs were treated with 0-25 μg/mL cordycepin and 5 ng/mL PS-341 (bortezomib) for 24 h. Expression of cleaved PARP was determined by Western blotting analysis. β-actin was used as loading control. ** p < 0.01, *** p < 0.005 Figure S3 . Cordycepin suppresses FAK expression and phosphorylation in HCC. Huh-7 cells were treated with 0-25 μg/mL cordycepin for 24 h. Expressions of FAK and p-FAK were determined by Western blotting analysis. β-actin was used as loading control. ** p < 0.01, *** p < 0.005 Figure S4 . Cordycepin inhibits cell proliferation of HCC. Huh-7, HepG2 and Hep3B cells were treated with 0-25 μg/mL cordycepin for 24 h or 48 h. Cell viability was determined by MTT assay. Scale bars: mean ± SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
Cells Culture Medium
HUVECs M200 medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Biological Industries, Kibbutz BeitHaemek, Israel), 100 unit/mL penicillin, 100 mg/mL streptomycin and low serum growth supplement (LSGS) (Gibco).
HCAECs
Endothelial cell growth medium (EGM™-2 MV) medium supplemented with 5% FBS, 0.04% hydrocortisone, 0.4% hFGF-B, 0.1% VEGF, 0.1% R3-IFG-1, 0.1% ascorbic acid, 0.1% hEGF, 0.1% gentamicin and amphotericin-B (GA-1000) (Lonza, Walkersville, MD, USA).
HPAECs
Endothelial cell growth medium-2 (EGM™-2) medium supplemented with 2% FBS, 0.04% hydrocortisone, 0.4% hFGF-B, 0.1% VEGF, 0.1% R3-IFG-1, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000, 0.1% heparin (Lonza). 
